Introduce us SMARTIMMUNE in a few words
Smart Immune, a clinical-stage biotechnology company, is developing a cell therapy platform called ProTcellTM. It exploits the physiology of the thymus to rearm the immune system in record time and “tolerate” the cells injected into the patient. This unprecedented approach makes possible a new generation of allogeneic cell therapies, potentially accessible to all patients who need them.
How do you judge the contribution of the MATWIN support program to the development of your project ?
We are grateful to have benefited from very high quality support, we were able to appreciate it as a whole: speech articulation , choice of a flagship project with the most innovative and structuring of an offer, presentation of the stages of development. The coaching sessions familiarized us with the expectations of an investors jury or potential industrial partners. What we are presenting today better enhances the potential of our platform, both for patients and for future partners.
What do you think are MATWIN’s advantages ?
MATWIN brings together the ingredients for success and puts them within the reach of biotechs. It was a real boost in our development to be able to access a network of peers, pharmas, investment experts and funders of course. The two distinctions that we brought back from the MEET2WIN convention rewarded our efforts with a useful and very appreciable spotlight!
How could MATWIN improve its action?
Continuing it, and internationalizing it ever more! We need to gather as much support as possible to bring the therapies of tomorrow to the bedside of patients.
